DexCom (DXCM)
(Delayed Data from NSDQ)
$68.11 USD
+2.43 (3.70%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $68.09 -0.02 (-0.03%) 5:16 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.11 USD
+2.43 (3.70%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $68.09 -0.02 (-0.03%) 5:16 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Zacks News
5 Best Stocks From 100 Days of Coronavirus
by Tirthankar Chakraborty
Here're five big stock winners from the first 100 days of the coronavirus pandemic that ravaged the global economy and shook the stock market.
The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive
3 MedTech Stocks to Watch Amid Coronavirus Catastrophe
by Trina Mukherjee
Let's keep a watch on three stocks that have displayed strong performance amid market turmoil led by the ongoing pandemic.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $393, moving -1.44% from the previous trading session.
Economic Recovery Debate Heats Up: 4 Sectors Holding Ground
by Urmimala Biswas
Here we discuss four sectors for which COVID-19 has opened up enormous growth prospects.
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $385.17, marking a +1.23% move from the previous day.
DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe
by Zacks Equity Research
DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.
ABIOMED Gets FDA Nod for First-in-Human Trial of Impella ECP
by Zacks Equity Research
This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product line.
Here's Why You Should Retain AmerisourceBergen Stock Now
by Zacks Equity Research
Investor confidence is high on AmerisourceBergen (ABC) stock, thanks to solid prospects.
Here's Why You Should Retain Ecolab in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Ecolab (ECL) stock, thanks to solid prospects.
Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
ABIOMED's (ABMD) Impella RP Receives FDA's EUA Clearance
by Zacks Equity Research
This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product portfolio.
Do You Always Look for Earnings Beat? 5 Sectors to Play
by Sanghamitra Saha
These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.
Here's Why You Should Add Accuray to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio
by Zacks Equity Research
DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.
DexCom (DXCM) Up 4.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Inogen in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Inogen (INGN) stock, thanks to solid prospects.
Varian (VAR) Unveils New Features for Noona Software
by Zacks Equity Research
This development, which is in response to the challenges brought on by the pandemic, is expected to boost Varian's (VAR) Oncology segment.
5 Health Care Stocks to Bet on as Coronavirus Woes Linger
by Sreoshi Bera
The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
S&P 500 Touches 3,000 Again: Winning Stocks of IVV ETF
by Sanghamitra Saha
The S&P 500 has rallied 1.2% on May 26, topping the 3,000-mark for the first time since Mar 5.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.
Here's Why You Should Retain Merit Medical (MMSI) for Now
by Zacks Equity Research
Investor confidence is high in Merit Medical (MMSI) stock, thanks to solid prospects.
Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform
by Zacks Equity Research
This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?